Improving CHC 2014 Program

ImprovingCHCBanner_v3

Jointly sponsored by:

PIM-4C-logo_sml   VE logo 300px
  

 

ScrollDown_ProgramCME_Button 

Reviewed_ProgramCME_Button 

About the Program

Program Overview

Health care providers caring for patients with chronic hepatitis C virus (HCV) infection now have a growing number of options for treating patients. While these choices provide important options, they also present new challenges. Some of the most significant issues facing health care providers today, especially those with limited experience or a small cohort of patients under their care, involve understanding and effectively utilizing the wealth of clinical research data assessing HCV treatment and regimen choices for treatment-naïve and treatment-experienced   patients. This situation can result in suboptimal therapy and outcomes for patients with chronic hepatitis C (CHC) infection.

This program has been designed to address this problem. This two-part medical education program includes a combination of online teaching modules and live Q&A sessions with nationally recognized CHC specialists. As a result of participating in this program, we anticipate that physicians and other health care providers will gain a greater understanding of how to provide optimal therapy for patients with CHC infection, thereby increasing the number of patients receiving individualized and effective CHC therapy, while reducing morbidity and mortality and improving patient outcomes.

The first part of the program includes a choice of three online modules that address: 1) Current Guidelines for the Diagnosis and Management of Patients with HCV Infection; 2) Overcoming Host and Viral Barriers to Successful Hepatitis C Therapy; and 3) Future Therapies for CHC: The Importance of New Treatment Paradigms and Interferon-free Regimens. Once a module is completed and CME credit has been awarded, the participant will be offered a unique opportunity to participate in an individual Q&A session via text, email, or teleconference, with  a member of our distinguished CHC faculty for a more in-depth discussion of the module topics.

Back to Top 

Target Audience

This activity is intended for physicians, physician assistants, advanced practice nurses, and other health care professionals involved in the treatment and management of patients with HCV infection. It is tuition-free and there are no prerequisites.

Back to Top

Program Objectives

Upon completion of the program, participants should be better able to:

  • Utilize current treatment guidelines for appropriate selection of CHC therapy for each patient
  • Implement strategies to overcome barriers to successful treatment of patients with CHC to improving patient care
  • Discuss with patients and colleagues studies and data on future treatments for patients with CHC to make appropriate decisions for each patient on whether it is appropriate to treat with current agents or wait for future therapeutic options
Back to Top

Course Directors and Faculty

Nezam H. Afdhal MD Nezam H. Afdhal, MD
Professor of Medicine
Harvard School of Medicine
Chief of Hepatology, Director of Liver Center,
Beth Israel Deaconess Medical Center
Boston, Massachusetts
     
K. Rajender Reddy MD K. Rajender Reddy, MD
Professor of Medicine
Professor of Medicine in Surgery
Director of Hepatology
Director, Viral Hepatitis Center
University of Pennsylvania
Philadelphia, Pennsylvania
Mark Sulkowski MD Mark Sulkowski, MD
Professor of Medicine and Medical Director
Viral Hepatitis Center
Johns Hopkins University School of Medicine
Baltimore, Maryland
     

Faculty Consultants

Maurizio Bonacini, MD
University of California San Francisco 
Douglas Dieterich, MD
Mount Sinai School of Medicine
Paul Gaglio, MD
Albert Einstein College of Medicine
James Hamilton, MD
Johns Hopkins University
Lennox Jeffers, MD
University of Miami
Paul Kwo, MD
Indiana University
David Nelson, MD
University of Florida
Natarajan Ravendhran, MD
Johns Hopkins University
Sammy Saab, MD
University of California Los Angeles
 
   
   

Back to Top  

Program Modules

1) Current Guidelines for the Diagnosis and Management of Patients with HCV Infection
2) Overcoming Host and Viral Barriers to Successful Hepatitis C Therapy
3) Future Therapies for CHC: The Importance of New Treatment Paradigms and Interferon-free Regimens

Media: Internet
Release Date: May 22, 2014 
Expiration Date: May 22, 2015

Please click button below to launch module menu. 
Click here to view Participation Instructions

CHC2014_LaunchProgram_Button_v2

Back to Top  

Post-Module Faculty Q&A Session

Upon the completion of each module, and passing the corresponding CME post-tests, each participant will have an opportunity to have a Q&A Session with one of the faculty members. This session can take place via email, text or teleconference. The primary purpose of this session will be to answer questions or provide information regarding the completed modules; however, other areas of interest may also be addressed at the discretion of the faculty member.

Note that once a Q&A session is requested, a confirmation will be sent within 48 hours of the request. Once the session request has been confirmed, any text/email requests will then be sent to a faculty member with a response from them given within one week of request. If a teleconference was requested, the scheduling process will begin for a 15-minute call which would be scheduled within one month of the initial request, based on faculty availability.

Click the button below to request a Q&A Session with a faculty member once you have completed a module and received CME credit.

CHC2014_Q&A_Button_v2

Back to Top  

Accreditation Statement

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Postgraduate Institute for Medicine and ViralEd, Inc.. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Back to Top

Credit Designation

Current Guidelines for the Diagnosis and Management of Patients with HCV Infection

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1 AMA PRA Category 1 CreditTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

 

Overcoming Host and Viral Barriers to Success Hepatitis C Therapy 

 

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Future Therapies for CHC: The Importance of New Treatment Paradigms and Interferon-free Regimens

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1 AMA PRA Category 1 CreditTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Back to Top

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Nezam Afdahl, MD

  • Contracted Research: Merck; Vertex; BMS; Abbott; Gilead; Idenix
  • Consulting Fees: Vertex; Merck; Gilead; BMS: Anadys; Abbott
  • Speakers' Bureau: Human Genome Sciences; Merck; Roche; BMS; Gilead; GlaxoSmithKline

K. Rajender Reddy, MD

  • Consulting Fee: Genentech Roche; Merck; Tibotec; Gilead; Vertex
  • Contracted Research: BMS; Gilead; Tibotec; Merck; Anadys; Pharmasset (UPENN)

Mark Sulkowski, MD

  • Contracted Research: BMS; Merck; Genentech/Roche; Vertex; Gilead; Boehringer Ingelheim; Janssen; Pharmasset; Abbott
  • Consulting Fees: BMS; Merck; Genentech/Roche; Vertex; Gilead; Boehringer Ingelheim; Janssen; Pharmasset; Abbott

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

The following PIM planners and managers, Laura Excell, ND, NP, MS, MA, LPC, NCC, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CCMEP, and Jan Schultz, RN, MSN, CCMEP hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months. 

Back to Top 

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Back to Top    

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Back to Top    

Method of Participation and Request for Credit

There are no fees for participating and receiving CME credit for this activity. During the period May 22, 2014 through May 22, 2015, participants must read the learning objectives and faculty disclosures and study the educational activity.

PIM supports Green CME by offering your Request for Credit online. If you wish to receive acknowledgment for completing this activity, please complete the post-test and evaluation on www.cmeuniversity.com. On the navigation menu, click on "Find Post-test/Evaluation by Course" and search by course ID (Sulkowski Module: 9903; Reddy Module: 9904; Afdhal Module: 9905.) Upon registering and successfully completing the post-test with a score of 70% or better and the activity evaluation, your certificate will be made available immediately. Processing credit requests online will reduce the amount of paper used by nearly 100,000 sheets per year.

 

CHC2014_LaunchProgram_Button_v2
     

ViralEdLogo-144x48.jpg Spacer_20x20  PIM-4C-logo_sml



ViralEd, LLC

http://www.viraled.com/modules/info/improving_chc_2014_program.html